Literature DB >> 31598791

Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening.

Jie Li1, Huawei Xu1, Lixing Zhang2, Lele Song1, Dan Feng1, Xiaobo Peng1, Meihong Wu1, Yang Zou3, Bin Wang1, Lixing Zhan4, Guoqiang Hua5, Xianbao Zhan6.   

Abstract

PURPOSE: Malignant ascites (MA) is a common manifestation in advanced gastric cancer with peritoneal carcinomatosis and usually indicates a poor prognosis. However, lack of in vitro models that can faithfully recapitulate the characteristics of tumour cells in ascites hinders related researches. Tumour organoids have emerged as a robust in vitro model for tumour research and drug screening. Hence, we aimed to generate a 3-D in vitro organoid cultures from malignant ascites of gastric cancer for disease modelling and drug screening.
METHODS: Eleven MADOs were generated from the MA tumour cells of gastric cancer patients. We made comparisons between MADOs and original MA tumour cells in histopathology by immunohistochemistry and genomics by whole-exome sequencing. In order to evaluate MADOs as functional in vitro disease models, we tested whether MADOs could be used for drug sensitivity screens.
RESULTS: Eleven MADO cultures from human gastric cancer were established. MADOs demonstrated divergent growth characteristics and morphologies. MADO cultures preserve the histological architecture, genomic landscape of the corresponding MA tumour cells. MADOs exhibited heterogeneous responses to standard-of-care chemotherapeutics.
CONCLUSIONS: We generated MADOs modelling characteristics and mutated genes of MA tumour cells. A broad range of intrinsic MADO response to conventional chemotherapeutics suggests MADOs are amenable to drug screening.

Entities:  

Keywords:  Drug screening; Gastric cancer; Malignant ascites; Organoid; Personalised medicine

Mesh:

Substances:

Year:  2019        PMID: 31598791     DOI: 10.1007/s00432-019-03004-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  44 in total

1.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

Review 2.  Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.

Authors:  Fleur Weeber; Salo N Ooft; Krijn K Dijkstra; Emile E Voest
Journal:  Cell Chem Biol       Date:  2017-07-27       Impact factor: 8.116

3.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.

Authors:  Razvan Cristescu; Jeeyun Lee; Michael Nebozhyn; Kyoung-Mee Kim; Jason C Ting; Swee Seong Wong; Jiangang Liu; Yong Gang Yue; Jian Wang; Kun Yu; Xiang S Ye; In-Gu Do; Shawn Liu; Lara Gong; Jake Fu; Jason Gang Jin; Min Gew Choi; Tae Sung Sohn; Joon Ho Lee; Jae Moon Bae; Seung Tae Kim; Se Hoon Park; Insuk Sohn; Sin-Ho Jung; Patrick Tan; Ronghua Chen; James Hardwick; Won Ki Kang; Mark Ayers; Dai Hongyue; Christoph Reinhard; Andrey Loboda; Sung Kim; Amit Aggarwal
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

4.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.

Authors:  Zhi Jiang Zang; Ioana Cutcutache; Song Ling Poon; Shen Li Zhang; John R McPherson; Jiong Tao; Vikneswari Rajasegaran; Hong Lee Heng; Niantao Deng; Anna Gan; Kiat Hon Lim; Choon Kiat Ong; DaChuan Huang; Sze Yung Chin; Iain Beehuat Tan; Cedric Chuan Young Ng; Willie Yu; Yingting Wu; Minghui Lee; Jeanie Wu; Dianne Poh; Wei Keat Wan; Sun Young Rha; Jimmy So; Manuel Salto-Tellez; Khay Guan Yeoh; Wai Keong Wong; Yi-Jun Zhu; P Andrew Futreal; Brendan Pang; Yijun Ruan; Axel M Hillmer; Denis Bertrand; Niranjan Nagarajan; Steve Rozen; Bin Tean Teh; Patrick Tan
Journal:  Nat Genet       Date:  2012-05       Impact factor: 38.330

5.  Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.

Authors:  Nian Fang; Hui-Qing Zhang; Bo He; Mei Xie; Shan Lu; Yi-Ye Wan; Nong-Rong Wang
Journal:  Tumour Biol       Date:  2013-11-27

6.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

Review 7.  Evaluation and treatment of malignant ascites secondary to gastric cancer.

Authors:  Hiromichi Maeda; Michiya Kobayashi; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

9.  Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.

Authors:  Suk Hyung Lee; Wenhuo Hu; Justin T Matulay; Mark V Silva; Tomasz B Owczarek; Kwanghee Kim; Chee Wai Chua; LaMont J Barlow; Cyriac Kandoth; Alanna B Williams; Sarah K Bergren; Eugene J Pietzak; Christopher B Anderson; Mitchell C Benson; Jonathan A Coleman; Barry S Taylor; Cory Abate-Shen; James M McKiernan; Hikmat Al-Ahmadie; David B Solit; Michael M Shen
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

10.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Authors:  Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz
Journal:  Nat Biotechnol       Date:  2013-02-10       Impact factor: 54.908

View more
  7 in total

Review 1.  Promises and Challenges of Organoid-Guided Precision Medicine.

Authors:  Shree Bose; Hans Clevers; Xiling Shen
Journal:  Med (N Y)       Date:  2021-09-10

2.  Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy.

Authors:  Guangyao Liu; Xing Xiao; Yujian Xia; Weibing Huang; Wei Chen; Jiannan Xu; Songyao Chen; Huijin Wang; Jitao Wei; Huan Li; Man Shu; Xiaofang Lu; Changhua Zhang; Yulong He
Journal:  Front Med (Lausanne)       Date:  2022-06-02

Review 3.  Organoid of ovarian cancer: genomic analysis and drug screening.

Authors:  H-D Liu; B-R Xia; M-Z Jin; G Lou
Journal:  Clin Transl Oncol       Date:  2020-01-14       Impact factor: 3.405

Review 4.  Patient-Derived Cancer Organoids as Predictors of Treatment Response.

Authors:  Maikel Verduin; Ann Hoeben; Dirk De Ruysscher; Marc Vooijs
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

Review 5.  Use of Patient-Derived Organoids as a Treatment Selection Model for Colorectal Cancer: A Narrative Review.

Authors:  Sara Furbo; Paulo César Martins Urbano; Hans Henrik Raskov; Jesper Thorvald Troelsen; Anne-Marie Kanstrup Fiehn; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

6.  Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition.

Authors:  Shaohua Xu; Ruolan Fan; Lu Wang; Weishen He; Haixia Ge; Hailan Chen; Wen Xu; Jian Zhang; Wei Xu; Yaqian Feng; Zhimin Fan
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

Review 7.  The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers.

Authors:  Ya-Ya Yu; Yan-Juan Zhu; Zhen-Zhen Xiao; Ya-Dong Chen; Xue-Song Chang; Yi-Hong Liu; Qing Tang; Hai-Bo Zhang
Journal:  Biomark Res       Date:  2022-10-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.